He Yuhang, Li Min, Su Jie, Ren Yixuan, Fareed Muhammad S, Shen Zhiqiang, Wang Panpan, Ji Qingxian, Wang Zhaopeng, Wan Daicao, Ma Ting, Yan Jiexi, Wang Kairong
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences. Lanzhou University, West Donggang Road 199, Lanzhou, 730000, PR China.
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences. Lanzhou University, West Donggang Road 199, Lanzhou, 730000, PR China; State Key Laboratory of Low Carbon Catalysis and Carbon Dioxide Utilization, Lanzhou Institute of Chemical Physics, Lanzhou, 730000, PR China.
Eur J Med Chem. 2025 Dec 5;299:118078. doi: 10.1016/j.ejmech.2025.118078. Epub 2025 Aug 20.
Lugdunin, a newly discovered antibiotic with a unique structure, emerged during a decade-long antibiotic discovery void and is considered a promising lead for combating drug-resistant bacteria. However, its narrow spectrum targeting only Gram-positive bacteria and its structural limitations have hindered its development and clinical application. Herein, inspired by our previous combinatorial modification strategies for lugdunin, we designed and synthesized a series of multi-cationic lugdunin derivatives using a biphenylmethyl modification on the tryptophan indole structure combined with multi-cationic amino acid mutations, aiming to expand its antimicrobial spectrum. Our results showed that the optimized derivative, Lug-15, exhibited strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including Escherichia coli and Pseudomonas aeruginosa. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Additionally, it demonstrated low hemolytic toxicity and significant therapeutic potential in various infection models, including keratitis caused by MRSA and P. aeruginosa, MRSA-induced pneumonia, thigh muscle infection, and wound infection, indicating Lug-15's broad-spectrum therapeutic potential. Therefore, this study overcomes the historical limitation of prior SAR attempts and offers a new lead for combating drug-resistant bacteria.
路邓霉素是一种新发现的具有独特结构的抗生素,在长达十年的抗生素发现空白期出现,被认为是对抗耐药细菌的一个有前景的先导化合物。然而,其仅靶向革兰氏阳性菌的窄谱抗菌特性及其结构局限性阻碍了它的开发和临床应用。在此,受我们之前对路邓霉素的组合修饰策略启发,我们设计并合成了一系列多阳离子路邓霉素衍生物,通过在色氨酸吲哚结构上进行联苯甲基修饰并结合多阳离子氨基酸突变,旨在扩大其抗菌谱。我们的结果表明,优化后的衍生物Lug-15对革兰氏阳性菌和革兰氏阴性菌均表现出强大的抗菌活性,包括大肠杆菌和铜绿假单胞菌。Lug-15主要通过破坏细胞膜快速杀灭细菌,且诱导细菌耐药的倾向极低。此外,它在各种感染模型中均表现出低溶血毒性和显著的治疗潜力,包括由耐甲氧西林金黄色葡萄球菌(MRSA)和铜绿假单胞菌引起的角膜炎、MRSA诱导的肺炎、大腿肌肉感染和伤口感染,表明Lug-15具有广谱治疗潜力。因此,本研究克服了以往构效关系研究尝试的历史局限性,为对抗耐药细菌提供了一种新的先导化合物。